# Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

> **NCT04487444** · PHASE2 · TERMINATED · sponsor: **Rhode Island Hospital** · enrollment: 56 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Thymalfasin

## Key facts

- **NCT ID:** NCT04487444
- **Lead sponsor:** Rhode Island Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-10
- **Primary completion:** 2023-02-03
- **Final completion:** 2023-02-03
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** The study was terminated due to slow enrollment and the transfer of the PI to another institution.
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04487444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04487444, "Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04487444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*